Research libraryTesting and sourcing
Third-Party Tested Peptides: How Purity Testing Actually Works
For laboratory research use only. The compounds discussed here are sold strictly for in vitro research. They are not drugs, supplements or cosmetics and are not for human or animal use. This article summarizes published literature for reference and is not medical or usage advice.
Third-party tested peptides sound like a marketing line until you look at what an independent lab actually measures. A vial label says “99%,” but that number only means something if you know which method produced it, what the method can’t see, and who ran it. We’ve read a fair amount of the analytical-chemistry literature on synthetic peptides, and the short version is this: purity is a stack of separate questions, and a single HPLC trace answers only one of them. Here’s how the testing works, where it falls short, and how to read a certificate of analysis without getting fooled.
Key findings
- Most synthetic peptides are made by solid-phase peptide synthesis, and that process leaves its own family of impurities: deletion and insertion sequences, diastereomers, protection-group adducts, oxidized residues and leftover counterions such as trifluoroacetate [1].
- Trifluoroacetate, carried over from reversed-phase HPLC, cut cell numbers in fetal rat osteoblast cultures at 10-8 to 10-7 M, enough to mask or fake an effect in the peptide being studied [2].
- A contaminating peptide too faint for direct mass spectrometry still triggered a T-cell response in a 2011 mouse study, and only showed up after LC concentration [3].
- Semaglutide vials bought from illegal online sellers in a 2024 study measured 7.7% to 14.37% purity against a labeled 99%, and every sample carried endotoxin [4].
- Falsified peptide products from Belgian internet sellers ranged from 5% to 75% purity for cysteine-containing peptides, and some held arsenic and lead [5].
Why a peptide is never just one molecule
Peptides come off the synthesizer as a mixture. Solid-phase synthesis builds the chain one residue at a time on a resin bead, and every coupling and deprotection step runs at a little under 100% efficiency. Miss one coupling and you get a deletion sequence, a peptide one residue short. Use too much reagent and you can get an insertion. Fmoc removal can flip the chirality of a residue, which gives you a diastereomer with the exact same mass as your target [1].
Then there’s the stuff that isn’t really “wrong peptide” at all. Side-chain protecting groups that didn’t come off cleanly leave adducts. Methionine and tryptophan oxidize. Some peptides stick together into dimers. And the final product almost always carries a counterion, often trifluoroacetate, from the cleavage cocktail or the purification step [1]. D’Hondt and colleagues, writing in a 2014 review of peptide-related impurities, also noted cases where a product was contaminated with entirely unrelated peptides, which they read as a sign of poor manufacturing control [1].
Why should a lab care? Because those impurities can do things. The same review pointed out that they can skew early functional studies enough to produce wrong conclusions [1]. That’s the whole argument for testing in one sentence.
What HPLC and mass spectrometry each tell you
Two methods carry most of the weight on a peptide certificate of analysis, and they answer different questions.
HPLC: how much of the sample is the main peak
Reversed-phase HPLC separates the components of a sample by how strongly they stick to a hydrophobic column. A UV detector set to a wavelength where the peptide bond absorbs draws a trace. Purity is reported as the main peak’s area divided by the total peak area. It’s a relative number. If an impurity co-elutes with your target, or doesn’t absorb at that wavelength, it simply isn’t counted.
Mass spectrometry: is the main peak the right molecule
MS weighs the molecule. If the observed mass matches the theoretical mass of the sequence, you have good evidence the main peak is what the label says. What MS can’t do on its own is tell apart residues with the same mass (leucine and isoleucine, for instance) or flag a D-amino acid swap. USP and MHRA scientists made this point in a 2023 paper on peptide reference standards, noting that chiral or isobaric residues may need extra techniques to fully confirm identity [6].
MS also has a sensitivity floor. In the 2011 Brezar study, mice developed CD8+ T cells against a contaminating peptide that direct mass spectrometry couldn’t detect. Only after concentrating the sample by liquid chromatography did the matching mass peak appear [3]. The authors’ conclusion was blunt: minute impurities in synthetic peptide preparations can give spurious results if nobody looks for them.
| Test | What it answers | What it can miss |
|---|---|---|
| RP-HPLC (UV) | Share of UV-absorbing material in the main peak | Co-eluting impurities, salts, water, non-absorbing contaminants |
| Mass spectrometry | Molecular mass matches the sequence | Isobaric residues, D/L swaps, trace contaminants below detection |
| Peptide content (mass balance or amino acid analysis) | How much of the powder by weight is peptide | Says nothing about which peptide species are present |
| Endotoxin (LAL) | Bacterial endotoxin load | Chemical purity |
| Elemental / residual solvent screens | Heavy metals, leftover solvents | Peptide identity |
Purity isn’t the same as peptide content
This trips up a lot of people. A sample can be 99% pure by HPLC and still be well short of 100% peptide by weight. The rest is water, counterion and other salts that HPLC doesn’t register. Pharmacopoeial monographs treat identity, purity and assay (how much active material is present) as separate specifications for exactly this reason, although Vergote and colleagues found in 2009 that the European and U.S. pharmacopoeias still differed a good deal in how they set those limits [7].
The reference-standard work from USP and MHRA shows how seriously the regulated world takes the content number. They assigned a value to bulk peptide material with a mass balance approach, then used that bulk material to assign a final value to each vial, and they ran identity and consistency checks across multiple labs [6]. Research suppliers don’t operate at that level, but it’s a useful picture of what “assay” really means.
The counterion problem
Trifluoroacetic acid is standard in reversed-phase purification, so plenty of peptides arrive as TFA salts. Most of the time nobody thinks about it. Cornish and colleagues did, back in 1999. TFA at 10-8 to 10-7 M reduced cell numbers and thymidine incorporation in fetal rat osteoblast cultures within 24 hours, and the effect showed up in chondrocytes and mouse calvariae too [2].
The part that should make anyone running cell work sit up: when they compared TFA and hydrochloride salts of amylin, amylin-(1-8) and calcitonin, the TFA versions consistently produced less proliferation. That was enough to hide a real proliferative effect or create a fake antiproliferative one [2]. They suggested converting peptides to a hydrochloride or equivalent salt before testing anything above about 10-9 M. Your COA usually won’t list counterion content unless you ask, and it’s worth asking.
What untested material looks like
We don’t have to guess what happens without independent checks, because regulators and academics have bought the stuff and run it.
A Belgian team analyzed the ten falsified peptide products seen most often on their market, sourced from three suspected illegal internet pharmacies. Amounts per unit varied widely, purity for cysteine-containing peptides ranged from 5% to 75%, and several samples carried arsenic at up to ten times the ICH limit, with one also contaminated by lead [5].
A 2024 study from Hungary and the U.S. made test purchases of semaglutide from illegal online sellers. The vials that arrived claimed 99% purity on the label. Measured purity came in at 7.7% to 14.37%. Peptide content overshot the label by 28.56% to 38.69%, and endotoxin was found in every sample, at 2.16 to 8.95 EU/mg [4]. Think about that combination for a second: too much material by weight, and most of it not the molecule you wanted. A single “purity” number on a label would never have told you that.
How to read a COA without getting fooled
A certificate of analysis is only as good as the lab behind it and how specific it is. Here’s what we look for.
First, the batch or lot number on the COA should match the vial. A generic certificate that covers “the product” rather than a specific lot isn’t worth much. Second, it should name the lab and the methods, and ideally include the actual HPLC chromatogram and mass spectrum rather than a typed percentage. If you can see the trace, you can see whether there’s a shoulder on the main peak or a cluster of small ones.
Third, check that the reported mass matches the theoretical mass for the sequence. Fourth, notice what isn’t there. No peptide content figure, no endotoxin result, no counterion information? That’s not automatically a red flag for basic bench work, but you should know the gap exists.
Independence matters because the manufacturer has an obvious interest in a good number. A U.S.-based third-party laboratory with no stake in the result is the closest a research buyer gets to the multi-lab cross-checking seen in pharmacopoeial work. You can see how our batches are documented on our certificates of analysis page.
If you’re newer to the chemistry side, our explainer on what peptides and polypeptides are covers the basics, and our piece on natural versus synthetic peptides goes deeper into how synthesis creates the impurity profile described above.
FAQ
Is 99% HPLC purity the same as 99% peptide?
No. HPLC purity is the share of UV-detectable material in the main peak. Water, salts and counterions don’t show up, so the peptide content by weight is usually lower.
Does mass spectrometry prove a peptide is pure?
It confirms the main species has the expected mass. It can miss isobaric residues, chirality changes and trace contaminants below its detection limit [3][6].
Why does third-party testing matter if the manufacturer already tests?
An independent lab has no stake in the result. The falsified-product studies above show how far label claims can drift from measured values when nobody outside checks [4][5].
References
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. J Pharm Biomed Anal. 2014. PMID 25044089
- Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Cooper GJ, Reid IR. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999. PMID 10567002
- Brezar V, Culina S, Østerbye T, et al. T cells recognizing a peptide contaminant undetectable by mass spectrometry. PLoS One. 2011. PMID 22194932
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024. PMID 39509151
- Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E. Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta. 2018. PMID 30029448
- McCarthy D, Han Y, Carrick K, et al. Reference Standards to Support Quality of Synthetic Peptide Therapeutics. Pharm Res. 2023. PMID 36949371
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009. PMID 19750489